- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 04.11. | BIOCON BIOLOGICS UK PLC: GENERAL ANNOUNCEMENT::PRESS RELEASE Q2FY27 | 6 | SGX Company Announcements | ||
| 26.10. | BIOCON BIOLOGICS UK PLC: GENERAL ANNOUNCEMENT::COMPANY STATEMENT | 2 | SGX Company Announcements | ||
| 14.10. | BIOCON BIOLOGICS UK PLC: GENERAL ANNOUNCEMENT::COMPANY STATEMENT | 3 | SGX Company Announcements | ||
| BIOCON BIOLOGICS Aktie jetzt für 0€ handeln | |||||
| 25.09. | BIOCON BIOLOGICS UK PLC: GENERAL ANNOUNCEMENT::COMPANY STATEMENT | 2 | SGX Company Announcements | ||
| 21.09. | BIOCON BIOLOGICS UK PLC: GENERAL ANNOUNCEMENT::PRESS RELEASE | 2 | SGX Company Announcements | ||
| 08.09. | BIOCON BIOLOGICS UK PLC: GENERAL ANNOUNCEMENT::PRESS RELEASE | 2 | SGX Company Announcements | ||
| 25.08. | BIOCON BIOLOGICS UK PLC: GENERAL ANNOUNCEMENT::COMPANY STATEMENT | 4 | SGX Company Announcements | ||
| 18.08. | BIOCON BIOLOGICS UK PLC: GENERAL ANNOUNCEMENT::COMPANY STATEMENT | 4 | SGX Company Announcements | ||
| 05.08. | BIOCON BIOLOGICS UK PLC: GENERAL ANNOUNCEMENT::PRESS RELEASE | 2 | SGX Company Announcements | ||
| 03.08. | BIOCON BIOLOGICS UK PLC: GENERAL ANNOUNCEMENT::PRESS RELEASE | 6 | SGX Company Announcements | ||
| 29.07. | BIOCON BIOLOGICS UK PLC: GENERAL ANNOUNCEMENT::COMPANY STATEMENT | 2 | SGX Company Announcements | ||
| 16.07. | BIOCON BIOLOGICS UK PLC: GENERAL ANNOUNCEMENT::COMPANY STATEMENT | 1 | SGX Company Announcements | ||
| 09.07. | BIOCON BIOLOGICS UK PLC: GENERAL ANNOUNCEMENT::PRESS RELEASE | 1 | SGX Company Announcements | ||
| 06.07. | BIOCON BIOLOGICS GLOBAL PLC: GENERAL ANNOUNCEMENT::BIOCON ISSUER SUBSTITUTION | 1 | SGX Company Announcements | ||
| 30.06. | BIOCON BIOLOGICS GLOBAL PLC: GENERAL ANNOUNCEMENT::FINANCIALS FOR QUARTER AND YEAR ENDED MARCH 31, 2026 | 1 | SGX Company Announcements | ||
| 24.06. | BIOCON BIOLOGICS GLOBAL PLC: GENERAL ANNOUNCEMENT::PRESS RELEASE | 2 | SGX Company Announcements | ||
| 06.12.25 | Viatris To Sell Equity Stake In Biocon Biologics To Biocon For $815 Mln | 1.113 | AFX News | NEW DELHI (dpa-AFX) - Viatris Inc. (VTRS) announced that it has entered into definitive agreements with Biocon Limited for the sale of its equity stake in Biocon Biologics Limited. Under the... ► Artikel lesen |
17 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PEPGEN | 4,620 | +0,22 % | PepGen soars on promising early data for muscular dystrophy drug | ||
| PRAXIS PRECISION MEDICINES | 337,27 | -0,09 % | Praxis Precision Medicines, Inc. - 10-Q, Quarterly Report | ||
| DISC MEDICINE | 84,77 | +0,15 % | Disc Medicine auf der Guggenheim-Konferenz: Finanzstarker Vorstoß in die Vermarktungsphase | ||
| ARCUTIS BIOTHERAPEUTICS | 27,385 | 0,00 % | Arcutis Biotherapeutics, Inc.: Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| DYNE THERAPEUTICS | 17,920 | 0,00 % | Dyne Therapeutics, Inc. - 8-K, Current Report | ||
| ERASCA | 15,480 | 0,00 % | Tango Therapeutics, Inc.; Erasca, Inc.: Tango and Erasca Initiate Phase 1/2 Study of Oral PRMT5 Inhibitor Vopimetostat in Combination with Pan-RAS Molecular Glue ERAS-0015 | ||
| EDGEWISE THERAPEUTICS | 46,570 | +0,09 % | Edgewise Therapeutics Announces Productive End-of-Phase 2 Meeting with FDA for EDG-7500 in HCM; Phase 3 Protocol Features Tolerability-Based Dose Escalation Without Safety Echo Monitoring | - Following the End-of-Phase 2 meeting, Edgewise has submitted the STRATUS-HCM Phase 3 protocol with dose escalation guided by investigator assessment of tolerability -- STRATUS-HCM includes two independent... ► Artikel lesen | |
| COGENT BIOSCIENCES | 31,600 | -0,13 % | Cogent Biosciences auf Guggenheim-Konferenz: Marktstart rückt näher | ||
| TANGO THERAPEUTICS | 24,280 | -0,08 % | Jefferies raises Tango Therapeutics stock price target on trial data | ||
| ABSCI | 9,970 | 0,00 % | Absci auf der Guggenheim-Gesundheitskonferenz: Eigene Pipeline rückt in den Fokus | ||
| KYMERA THERAPEUTICS | 136,60 | -0,03 % | Kymera International Appoints Willson Ropp as Chief Executive Officer | Experienced specialty materials executive brings more than 30 years of leadership experience across global manufacturing, operational excellence, business integration, and long-term value... ► Artikel lesen | |
| BEAM THERAPEUTICS | 25,160 | +0,04 % | Jones Trading initiates Beam Therapeutics stock coverage with buy rating | ||
| ENLIVEN THERAPEUTICS | 51,29 | +0,18 % | Enliven Therapeutics, Inc.: Enliven Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Business Update | Reached alignment with the FDA on the final design of the ENABLE-2 pivotal Phase 3 trial On track to initiate ENABLE-2 before year-end 2026 Strong balance sheet with $884 million in cash, cash equivalents... ► Artikel lesen | |
| JANUX THERAPEUTICS | 12,040 | 0,00 % | Janux reports phase 1 data for autoimmune drug candidate JANX011 | ||
| RECURSION PHARMACEUTICALS | 3,550 | 0,00 % | Recursion Pharmaceuticals (NDQ:RXRX): Why Is Nvidia An Investor? Because Its AI Platform Could Change Drug Discovery, Or Could It? |
BIOCON BIOLOGICS GLOBAL PLC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 98,45 Euro und damit -0,22 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIOCON BIOLOGICS GLOBAL PLC finden Sie auf Wallstreet Online.